Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Venetoclax in Renal Impairment
NCT04810598Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in hematologic malignancy (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events up to 38 days, Maximum Plasma Concentration of Venetoclax and 6 more. Started Jul 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04810598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810598.